Halal pharmaceuticals market: size, growth and outlook 2026–2032

A growing certification requirement across Southeast Asia and the GCC that suppliers cannot ignore. Published estimates normalised to 2025 range from USD 122 bn to USD 122 bn; the Consulting Wallah central estimate is USD 118 bn, growing at about 7% a year to USD 189 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by global Muslim population >1.9 bn with pharma/health spend growing 6.8% CAGR to USD 149 bn by 2028; indonesia's mandatory halal certification (GR 42/2024: supplements/traditional medicine Oct 2026, OTC Oct 2029, Rx Oct 2034) creating compliance-led demand; maturing certification frameworks: Malaysia MS 2424 (2012, rev. 2019) with JAKIM-NPRA cooperation; OIC/SMIIC 8:2020 common guideline.

Context that matters for buyers and suppliers: Malaysia introduced MS 2424 Halal Pharmaceutical Guidelines in 2012 (began developing standards in 1999); current version MS 2424:2019; JAKIM certifies in cooperation with NPRA. OIC/SMIIC 8:2020 is the OIC common guideline for halal pharmaceutical products; adoption varies by country. Indonesia's BPJPH (Ministry of Religious Affairs) oversees halal certification with technical assessment by Halal Inspection Bodies; GCC guidelines being developed via GSO, not yet mandatory. Top three Muslim pharma-spend countries: Turkey, Saudi Arabia, Iran; fastest growing: Indonesia, Malaysia, Egypt.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 122 bn–USD 122 bn; differences are mostly scope.

Included: the therapeutic category as named, originator and generic/biosimilar, across hospital and retail channels. Excluded: adjacent classes, devices used for delivery. Price basis (list vs net) differs between publishers.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Malaysia introduced MS 2424 Halal Pharmaceutical Guidelines in 2012 (began developing standards in 1999); current version MS 2424:2019; JAKIM certifies in cooperation with NPRA (Inkwood Research / HalalExpo)
• OIC/SMIIC 8:2020 is the OIC common guideline for halal pharmaceutical products; adoption varies by country (HalalExpo blog)
• Indonesia's BPJPH (Ministry of Religious Affairs) oversees halal certification with technical assessment by Halal Inspection Bodies; GCC guidelines being developed via GSO, not yet mandatory (HalalExpo blog / GlobalDeal)
• Top three Muslim pharma-spend countries: Turkey, Saudi Arabia, Iran; fastest growing: Indonesia, Malaysia, Egypt (Salaam Gateway)
• Asia-Pacific holds ~62% of global Muslim population and dominates halal pharma market (Inkwood Research)
• Saudi Arabia and UAE lead MEA local pharma manufacturing initiatives; Embil (Jordan) a leading regional halal player (Inkwood via ASDReports)
• Malaysia's halal logo may be used only on OTC (non-Poison List), traditional, supplement and cosmetic products, certified by JAKIM (MIDA Pharmaceutical SIB 2024)

Where the GCC and India sit

• Global Muslim spend on pharma & health products: USD 107 bn (2023) — Salaam Gateway / DinarStandard
• Global Muslim spend on pharma & health products (forecast): USD 149 bn (2028) — Salaam Gateway / DinarStandard
• MEA halal pharma CAGR: 9.32% (2025-2032) (2025) — Inkwood via ASDReports
• Malaysia halal pharma CAGR: 9.85% (2025-2032) (2025) — Inkwood Research
• Duopharma Biotech revenue (Malaysia halal leader): MYR 813.7 mn (+15.5%); net profit MYR 62.65 mn (2024) — The Star

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: halal-certified excipients and empty capsules (gelatin alternatives); export of Malaysian halal pharma to Indonesia ahead of 2029/2034 deadlines (Duopharma strategy); halal vaccines and biopharmaceuticals (Bio Farma, AJ Biologics, Hayat Biotech).

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: run the category as a tender lot with clinical sign-off; where biosimilars or generics exist, a switch programme with a validated savings tracker is the fastest saving.
• Manufacturers: GCC registration ahead of patent expiries and supply reliability win multi-year contracts; India is the manufacturing base to partner with.
• Payers: formulary rules that prefer the generic or biosimilar are the largest cost lever available.

1. Salaam Gateway, Halal Pharmaceuticals Sector Snapshot 2024/25 — salaamgateway.com
2. TechNavio via GII Research, Global Halal Pharmaceuticals Market 2026-2030 — giiresearch.com
3. Inkwood Research, Global Halal Pharmaceuticals Market Forecast 2025-2032 — inkwoodresearch.com
4. Inkwood Research, Halal Pharmaceuticals Market: Key Insights & Opportunities — inkwoodresearch.com
5. Inkwood via ASDReports, Middle East & Africa Halal Pharmaceuticals Market Forecast 2025-2032 — asdreports.com
6. The Star, Duopharma Biotech eyes more halal exports to Indonesia — thestar.com.my
7. HalalExpo blog, Halal pharmaceutical market trends — 99-halalexpo.vercel.app
8. DinarStandard / Salaam Gateway (State of the Global Islamic Economy) (2025-07) — USD 107 bn (Muslim spend on pharmaceuticals and health products) (2023) to USD 149 bn (2028), CAGR 6.8%; scope: Global: total Muslim consumer spend on pharma/health products (demand proxy, not halal-certified sales); top spenders Turkey, Saudi Arabia, Iran — source
9. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
10. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.